Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ATB THERAPEUTICS from Marche-en-Famenne, company number BE0677980015, closed financial year 2025 with a result of € -8 million after tax. For that financial year ATB THERAPEUTICS recorded a gross margin of € -513,236 and equity of € 5.1 million. Compared with financial year 2024, the result moved from € -3.3 million to € -8 million. The company made a loss. The buffer shrank hard: equity is 61 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 5.1 million
▼ 61% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -8 million
▼ 143 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1.9 million
▼ 86% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -15.5 million.
People and assets in 2025
17
▲ 7.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.9 million
▲ 140% vs 2024
€ 110,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 498,173
▲ € 445,689 vs 2024
Of which on lease € 424,439.
Debts at end 2025
€ 404,706
▲ € 353,360 vs 2024
€ 131,665 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1.6 million
▲ 112% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 510,830
▲ 252% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 407,078 | € -50,994 | € -885,092 | € -513,236 | ▲ € 371,855 |
| Profit after taxes | € -1,350,862 | € -2,127,736 | € -3,287,965 | € -7,995,905 | ▼ € 4.7 million |
| Equity | € -1,034,824 | € -3,162,560 | € 13,077,656 | € 5,081,751 | ▼ 61% |
| Total debts | € 3,217,974 | € 5,307,740 | € 955,499 | € 5,557,769 | ▲ € 4.6 million |
| Cash | € 908,181 | € 978,560 | € 13,500,259 | € 1,859,396 | ▼ 86% |
| Retained profit | € -2,120,338 | € -4,248,074 | € -7,536,039 | € -15,531,944 | ▼ € 8 million |
| Bank debt | € 2,624,769 | € 4,046,223 | € 51,346 | € 404,706 | ▲ € 353,360 |
| Balance sheet total | € 2,183,150 | € 2,145,180 | € 14,033,155 | € 10,639,520 | ▼ 24% |
| Employees (FTE) | 13.5 | 11.4 | 9.6 | 17 | ▲ 7.4 |
Key figures of ATB THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ATB THERAPEUTICS?
What happened at ATB THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Magman stepped down as director. NBB
- MRL Ventures Fund LLC stepped down as director. NBB
- LSP 7 Coöperatief U.A. stepped down as director. NBB
- CAPITAL ET CROISSANCE stepped down as director. NBB
- CHITON ROCKS stepped down as director. NBB
- V-Bio Fund 2 stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 8 million. Source: NBB ↗
- New establishment in Gent. KBO
In short
From € 1.4 million loss in 2022 to € 8 million loss in 2025.
On average € 30,200 of value added per employee in 2022.
A new publication or filing at ATB THERAPEUTICS? We notify you, reason included.
Follow ATB THERAPEUTICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NOSHAQ SPIN-OFFS, INVESTSUD TECH, Vives Inter-University Fund, INVESTSUD, INVESTSUD INNOVATION comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ATB THERAPEUTICSThe shares are held by NOSHAQ SPIN-OFFS (14.2%), INVESTSUD TECH (14.2%), Vives Inter-University Fund (5%), INVESTSUD (2.1%) and INVESTSUD INNOVATION (0.9%).
Directors
According to the 2025 annual accounts
Managing director · represented by Bertrand Magy
since 2024 · until 2030
Director · represented by Karin Kleinhans
since 2024 · until 2030
Director · represented by John de Koning, Vincent Brichard
since 2024 · until 2030
Director · represented by Pierre Detrixhe
Also active at: CONCEPTEXPO GROUP, COLONA, MEGAFORM, SUPERPLASTIC, SOCIETE COMMERCIALE ET INDUSTRIELLE, BAUWENS ROGER, SOGECAM, HORUS SOFTWARE +29 more
since 2024 · until 2030
CHITON ROCKS
Director · represented by Mark Throsby
since 2024 · until 2030
since 2024 · until 2030
Shareholders
14.2%
14.2%
2.1%
0.9%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Aye, Rue de la Science 8
6900 Marche-en-Famenne
Suzanne Tassierstraat 1
9052 Gent
Active since 1 June 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →Association pour le développement des Productions Agroalimentaires de qualité
CER-Groupe
€ 22.4 million revenue · 2025
Association pour l'Usage et la Défense de l'Appellation Jambon d'Ardenne
Orgenesis (Belgium)
€ 1.4 million gross margin · 2021
RevaTis
€ 136,602 gross margin · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0677.980.015
- VAT number
- BE 0677.980.015
- Registered office
- Aye, Rue de la Science 8, 6900 Marche-en-Famenne
- Names & denominations
- ATB THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 2017
- Peppol
- Active · Active since 7 Jul 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van farmaceutische grondstoffen
Teelt van specerijgewassen en van aromatische en medicinale gewassen